- Home
- FLXS vs DRUG Comparison
FLXS vs DRUG Comparison
Compare FLXS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLXS
- DRUG
- Stock Information
- Founded
- FLXS 2001
- DRUG 2019
- Country
- FLXS United States
- DRUG United States
- Employees
- FLXS N/A
- DRUG N/A
- Industry
- FLXS Home Furnishings
- DRUG Pharmaceuticals and Biotechnology
- Sector
- FLXS Consumer Discretionary
- DRUG Health Care
- Exchange
- FLXS Nasdaq
- DRUG Nasdaq
- Market Cap
- FLXS 224.2M
- DRUG 210.7M
- IPO Year
- FLXS N/A
- DRUG N/A
- Fundamental
- Price
- FLXS $59.99
- DRUG $46.62
- Analyst Decision
- FLXS
- DRUG
- Analyst Count
- FLXS 0
- DRUG 0
- Target Price
- FLXS N/A
- DRUG N/A
- AVG Volume (30 Days)
- FLXS 38.8K
- DRUG 9.2M
- Earning Date
- FLXS 10-21-2024
- DRUG 11-18-2024
- Dividend Yield
- FLXS 1.14%
- DRUG N/A
- EPS Growth
- FLXS N/A
- DRUG N/A
- EPS
- FLXS 2.50
- DRUG N/A
- Revenue
- FLXS $422,156,000.00
- DRUG N/A
- Revenue This Year
- FLXS $7.03
- DRUG N/A
- Revenue Next Year
- FLXS $4.99
- DRUG N/A
- P/E Ratio
- FLXS $23.90
- DRUG N/A
- Revenue Growth
- FLXS 7.53
- DRUG N/A
- 52 Week Low
- FLXS $15.72
- DRUG $0.93
- 52 Week High
- FLXS $60.58
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- FLXS 72.13
- DRUG 62.60
- Support Level
- FLXS $58.85
- DRUG $40.94
- Resistance Level
- FLXS $60.58
- DRUG $50.25
- Average True Range (ATR)
- FLXS 3.65
- DRUG 7.15
- MACD
- FLXS 0.22
- DRUG -0.95
- Stochastic Oscillator
- FLXS 95.93
- DRUG 33.29
About FLXS Flexsteel Industries Inc.
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.